Full text is available at the source.
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
Safety and body response to rising doses of HEC88473, a new drug acting on metabolism, in healthy and obese Chinese adults
AI simplified
Abstract
HEC88473 demonstrated significant glucose reduction of -1.829 mmol/L after baseline adjustment at the 47.6-mg dose in healthy participants.
- Absorption of HEC88473 occurred slowly, with maximum serum concentrations reached between 12.00-14.00 hours after dosing.
- Geomean half-lives for HEC88473, its GLP-1 component, and FGF21 component ranged from 16.2-22.6 hours, 66.5-119.5 hours, and 28.4-41.6 hours, respectively.
- Serum glucose levels decreased in healthy subjects after administration of doses ≥ 5.1 mg, with notable effects observed at days 3 and 7.
- Adiponectin levels increased up to 90.71% from baseline at the 62.9-mg dose, indicating a potential positive trend with higher doses.
- Triglyceride levels decreased by up to -43.01% from baseline at the 62.9-mg dose, suggesting a dose-dependent effect.
- HEC88473 was well tolerated, with mild gastrointestinal disorders being the most common treatment-related adverse events.
AI simplified